Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
about
The Role of Sialyl-Tn in CancerProteomic Upregulation of Fatty Acid Synthase and Fatty Acid Binding Protein 5 and Identification of Cancer- and Race-Specific Pathway Associations in Human Prostate Cancer Tissues.Recent advances in the tumour biology of the GPI-anchored carcinoembryonic antigen family members CEACAM5 and CEACAM6.The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killingDiagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature.Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies.Glandular lesions of the urinary bladder:clinical significance and differential diagnosis.Nephrogenic adenoma of the urinary tract: a review.Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer.Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.Double-fluorescence image microscopy for quantitation of prostate-specific antigen in histologic sections of the prostate.The role of glycans in the development and progression of prostate cancer.Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.Co-existence of mucin-producing urothelial-type adenocarcinoma of the prostate and inverted papilloma of the bladder.Evaluation of a triple combination of cytokeratin 20, p53 and CD44 for improving detection of urothelial carcinoma in urine cytology specimens.CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity.Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases.Value of claudin-4 immunostaining in the diagnosis of mesothelioma.Immunohistochemical panel of undifferentiated orbital metastatic carcinomas.Do HOXB13 and P63 have a role in differentiating poorly differentiated prostatic carcinoma from urothelial high-grade carcinoma?Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2-6 sialic acidsPAX2: a reliable marker for nephrogenic adenomaHOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin
P2860
Q28075448-005775FA-60FD-4652-916A-9377D3B77939Q30357469-8620D5A6-2621-45D6-905E-009B23AE3C42Q35840406-D7A5DFAB-6B07-4AAF-98F1-B30DF8436EFCQ36126003-0A2D4C30-E4A1-4BF2-8D32-583296A8616EQ36176427-213849FE-69BB-448B-AD95-3847EE9B6AECQ37297806-B5DAD4AD-8042-46BC-B821-5E98CEA30D5FQ37397581-2C8387ED-1464-41E0-A2EC-CA0D62145B4AQ37790432-7960A1E5-F49D-4525-A9E2-0452F6005015Q37993389-08CE60AD-111C-4C58-9C0E-EDDB7B508652Q37996298-4D9AF8D8-C71C-464B-AF26-9F60E243BB58Q38259961-459ADFBE-A340-4C33-A60C-530E8FFD452EQ38391360-47C3805B-4506-4F4B-B617-6A5333199347Q38455988-E9A2063A-31D1-4C12-AC82-BD8BCA1C90B6Q38811520-79C5693B-7025-4444-BD35-9F5AB6571B2EQ41358553-ECEFCAF6-2B59-4CDF-AAA4-DA9C210ABC44Q41691636-9FDED7C5-469D-4E3F-8968-2ACD08DE7709Q41839758-9ED3899E-46F8-4964-8289-3F27C99C336BQ42511446-25E0E4D7-EAD9-4C93-8E13-59E04DDB5101Q46391419-768A9D1B-12D9-42EF-AAFF-5D07577CF6A6Q50901820-A5043EA9-66EE-4257-95C1-13AD68EC362AQ51062851-0FB08F6A-CF0B-48AC-9412-FFF253ED7087Q51747342-D64DB9CC-5814-4168-BE7B-64065B63B2F9Q53413757-05E0EA9B-B7C5-42B0-9D17-26F30EA26AF7Q53572699-D91038C3-6E04-4A42-8864-C19BAB615E16Q57169347-482E6246-86BC-4620-97E3-DDE3D9FF6A0BQ57385843-C1DC6EF1-93BB-4A20-93F4-3771C7713346Q57565094-05FA86AF-E76D-4BCC-9CDF-C30CACA63470
P2860
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
@ast
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
@en
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
@nl
type
label
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
@ast
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
@en
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
@nl
prefLabel
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
@ast
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
@en
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
@nl
P2093
P2860
P3181
P1433
P1476
Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
@en
P2093
B Hutchinson
E M Genega
P B Gaudin
V E Reuter
P2860
P2888
P304
P3181
P356
10.1038/MODPATHOL.3880220
P407
P577
2000-11-01T00:00:00Z
P5875
P6179
1047821732